An ophthalmic product development company focused on ophthalmic pharmaceutical products based on its DuraSite(r) eyedrop-based drug delivery technology, developing genetically-based technologies for the diagnosis, prognosis & management of glaucoma.
The best Bull and Bear pitches based on recency and number of recommendations.
This has turned out to be my worst pick, both on the CAPS board and in real life. I am still sold on this company though and feel that it will have a fantastic ride up as soon as it gets noticed. The company recieved FDA approval for its AzaSite… More
I would suppose that this stock will continue to rise short-term, but where's the long-term future in this?
Read the most recent pitches from players about INSV.DL.
Find the members with the highest scoring picks in INSV.DL.
See what the Wall Street professionals think, according to their public statements and filings.